BiotechTube
Jazz Pharmaceuticals

Jazz Pharmaceuticals

JAZZApproved
Dublin, IrelandFounded 2003jazzpharma.com

Jazz Pharmaceuticals (NASDAQ: JAZZ) is a Dublin-based global biopharmaceutical company focused on transforming the lives of patients with rare diseases through innovative therapeutics. With a proven track record in developing and commercializing treatments for rare epilepsies, oncology, and sleep disorders, the company operates across nearly 100 countries with manufacturing facilities in the U.S., U.K., Ireland, and throughout Europe. Led by President and CEO Renee Gala, Jazz combines a patient-focused approach with science-driven research to advance a robust pipeline of innovative therapeutics targeting unmet medical needs.

Market Cap
$11.1B
+27.2% period
Pipeline
264
78 in Phase 3
Patents
20
granted
Publications
20
indexed

JAZZ · Stock Price

USD 180.62+38.60 (+27.18%)

Historical price data

AI Company Overview

Jazz Pharmaceuticals (NASDAQ: JAZZ) is a Dublin-based global biopharmaceutical company focused on transforming the lives of patients with rare diseases through innovative therapeutics. With a proven track record in developing and commercializing treatments for rare epilepsies, oncology, and sleep disorders, the company operates across nearly 100 countries with manufacturing facilities in the U.S., U.K., Ireland, and throughout Europe. Led by President and CEO Renee Gala, Jazz combines a patient-focused approach with science-driven research to advance a robust pipeline of innovative therapeutics targeting unmet medical needs.

Rare DiseasesOncologyNeurologySleep DisordersRare Epilepsies

Technology Platform

Jazz focuses on identifying, developing, and commercializing products for rare diseases with limited therapeutic options, leveraging both internal R&D and strategic acquisitions to transform biopharmaceutical discoveries into novel medicines.

Pipeline

264
264 drugs in pipeline78 in Phase 3
DrugIndicationStageWatch
JZP258NarcolepsyApproved
Cannabidiol Oral Solution [Epidiolex]Tuberous Sclerosis Complex Associated Neuropsychiatric DiseaseApproved
Cannabidiol (Epidiolex)Study the Efficacy of Epidiolex for Typical Absence SeizuresApproved
JZP-258NarcolepsyApproved
Solriamfetol + PlaceboBinge Eating DisorderApproved

Funding History

4
Total raised:$617M
Debt$500MJun 15, 2014
IPO$90MMay 30, 2007
Series A$27MJun 15, 2004
SeedUndisclosedJun 15, 2003

FDA Approved Drugs

9
MODEYSONDAAug 6, 2025
ZIIHERABLANov 20, 2024
RYLAZEBLAJun 30, 2021

Opportunities

Jazz is well-positioned to capitalize on the growing rare disease market through pipeline advancement, global expansion into Asian markets, and continued strategic acquisitions.
The company's focus on deepening its commitment to rare disease innovation presents significant growth opportunities in underserved therapeutic areas.

Risk Factors

Key risks include regulatory challenges in rare disease development, potential competition from larger pharmaceutical companies, and dependence on successful pipeline execution.
Market access and reimbursement challenges for high-cost rare disease therapies also present ongoing risks.

Competitive Landscape

Jazz competes in specialized rare disease markets where it has established leadership positions through deep expertise and strong physician relationships. The company differentiates itself through its global commercial infrastructure, patient-focused approach, and strategic focus on diseases with high unmet medical needs and limited competition.